vs

Side-by-side financial comparison of ESCALADE INC (ESCA) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $62.6M, roughly 1.2× ESCALADE INC). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -2.2%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $13.7M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 4.5%).

Escalade Inc is a global sporting goods manufacturer and distributor that offers basketball systems, archery equipment, table tennis gear, game tables, and outdoor recreation accessories. It operates primarily across North America, Europe, and Asia Pacific, serving consumer retail, commercial fitness, and specialty sports segments.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

ESCA vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.2× larger
PBYI
$75.5M
$62.6M
ESCA
Growing faster (revenue YoY)
PBYI
PBYI
+29.9% gap
PBYI
27.7%
-2.2%
ESCA
More free cash flow
PBYI
PBYI
$732.0K more FCF
PBYI
$14.4M
$13.7M
ESCA
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
4.5%
ESCA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESCA
ESCA
PBYI
PBYI
Revenue
$62.6M
$75.5M
Net Profit
$3.7M
Gross Margin
27.7%
69.3%
Operating Margin
8.2%
22.7%
Net Margin
5.9%
Revenue YoY
-2.2%
27.7%
Net Profit YoY
37.1%
EPS (diluted)
$0.27
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESCA
ESCA
PBYI
PBYI
Q4 25
$62.6M
$75.5M
Q3 25
$67.8M
$54.5M
Q2 25
$54.3M
$52.4M
Q1 25
$55.5M
$46.0M
Q4 24
$63.9M
$59.1M
Q3 24
$67.7M
$80.5M
Q2 24
$62.5M
$47.1M
Q1 24
$57.3M
$43.8M
Net Profit
ESCA
ESCA
PBYI
PBYI
Q4 25
$3.7M
Q3 25
$5.6M
$8.8M
Q2 25
$1.8M
$5.9M
Q1 25
$2.6M
$3.0M
Q4 24
$2.7M
Q3 24
$5.7M
$20.3M
Q2 24
$2.8M
$-4.5M
Q1 24
$1.8M
$-4.8M
Gross Margin
ESCA
ESCA
PBYI
PBYI
Q4 25
27.7%
69.3%
Q3 25
28.1%
77.7%
Q2 25
24.7%
76.5%
Q1 25
26.7%
77.1%
Q4 24
24.9%
76.4%
Q3 24
24.8%
63.9%
Q2 24
24.2%
77.4%
Q1 24
25.0%
75.5%
Operating Margin
ESCA
ESCA
PBYI
PBYI
Q4 25
8.2%
22.7%
Q3 25
10.8%
17.6%
Q2 25
4.8%
12.7%
Q1 25
6.6%
8.7%
Q4 24
7.1%
22.6%
Q3 24
11.8%
27.4%
Q2 24
7.1%
-4.6%
Q1 24
5.3%
-5.3%
Net Margin
ESCA
ESCA
PBYI
PBYI
Q4 25
5.9%
Q3 25
8.2%
16.2%
Q2 25
3.4%
11.2%
Q1 25
4.7%
6.5%
Q4 24
4.2%
Q3 24
8.4%
25.2%
Q2 24
4.5%
-9.6%
Q1 24
3.1%
-11.0%
EPS (diluted)
ESCA
ESCA
PBYI
PBYI
Q4 25
$0.27
$0.26
Q3 25
$0.40
$0.17
Q2 25
$0.13
$0.12
Q1 25
$0.19
$0.06
Q4 24
$0.20
$0.40
Q3 24
$0.40
$0.41
Q2 24
$0.20
$-0.09
Q1 24
$0.13
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESCA
ESCA
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$18.5M
$22.7M
Stockholders' EquityBook value
$173.2M
$130.3M
Total Assets
$222.1M
$216.3M
Debt / EquityLower = less leverage
0.11×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESCA
ESCA
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
ESCA
ESCA
PBYI
PBYI
Q4 25
$18.5M
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$25.6M
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
ESCA
ESCA
PBYI
PBYI
Q4 25
$173.2M
$130.3M
Q3 25
$172.3M
$115.3M
Q2 25
$168.3M
$104.7M
Q1 25
$168.8M
$97.1M
Q4 24
$169.0M
$92.1M
Q3 24
$170.1M
$71.1M
Q2 24
$166.0M
$48.5M
Q1 24
$164.7M
$51.0M
Total Assets
ESCA
ESCA
PBYI
PBYI
Q4 25
$222.1M
$216.3M
Q3 25
$232.5M
$202.9M
Q2 25
$218.3M
$194.9M
Q1 25
$222.1M
$196.2M
Q4 24
$226.3M
$213.3M
Q3 24
$244.9M
$220.7M
Q2 24
$243.1M
$205.0M
Q1 24
$256.3M
$214.1M
Debt / Equity
ESCA
ESCA
PBYI
PBYI
Q4 25
0.11×
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.15×
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESCA
ESCA
PBYI
PBYI
Operating Cash FlowLast quarter
$14.9M
$14.4M
Free Cash FlowOCF − Capex
$13.7M
$14.4M
FCF MarginFCF / Revenue
21.8%
19.1%
Capex IntensityCapex / Revenue
2.0%
0.0%
Cash ConversionOCF / Net Profit
4.02×
TTM Free Cash FlowTrailing 4 quarters
$28.5M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESCA
ESCA
PBYI
PBYI
Q4 25
$14.9M
$14.4M
Q3 25
$-965.0K
$9.7M
Q2 25
$13.3M
$14.1M
Q1 25
$3.8M
$3.6M
Q4 24
$12.3M
$15.6M
Q3 24
$10.5M
$11.0M
Q2 24
$13.3M
$1.0M
Q1 24
$7.0K
$11.2M
Free Cash Flow
ESCA
ESCA
PBYI
PBYI
Q4 25
$13.7M
$14.4M
Q3 25
$-1.3M
$9.7M
Q2 25
$12.9M
$14.1M
Q1 25
$3.2M
$3.6M
Q4 24
$11.7M
$15.6M
Q3 24
$10.2M
$11.0M
Q2 24
$12.5M
$1.0M
Q1 24
$-350.0K
FCF Margin
ESCA
ESCA
PBYI
PBYI
Q4 25
21.8%
19.1%
Q3 25
-1.9%
17.7%
Q2 25
23.7%
26.8%
Q1 25
5.9%
7.7%
Q4 24
18.4%
26.4%
Q3 24
15.0%
13.7%
Q2 24
20.0%
2.1%
Q1 24
-0.6%
Capex Intensity
ESCA
ESCA
PBYI
PBYI
Q4 25
2.0%
0.0%
Q3 25
0.4%
0.0%
Q2 25
0.8%
0.0%
Q1 25
1.0%
0.1%
Q4 24
0.9%
0.0%
Q3 24
0.5%
0.0%
Q2 24
1.3%
0.0%
Q1 24
0.6%
0.0%
Cash Conversion
ESCA
ESCA
PBYI
PBYI
Q4 25
4.02×
Q3 25
-0.17×
1.10×
Q2 25
7.28×
2.41×
Q1 25
1.45×
1.21×
Q4 24
4.55×
Q3 24
1.85×
0.54×
Q2 24
4.67×
Q1 24
0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons